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INTRODUCTION 
 A biomarker is a characteristic that can be objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmacological responses 
to a therapeutic intervention.  The ideal platforms for biomarker discovery include genomic, 
transcriptomic, proteomic, metabolomic and imaging analyses.  Many commonly used tests 
in clinical practice can serve as biomarkers, and the majority have been identified on the 
basis of insight or underlying physiology or biological mechanisms [1].  Abnormal uterine 
bleeding (AUB), is an extremely common problem and represents a clinical area of unmet 
need. Identifying potential biomarkers in this area would allow for planning individualised 
care. 
AUB was re-defined by Federation International de Gynecologie et d'Obstetrique 
(FIGO) in 2009 to introduce standardisation of nomenclature and identify an etiological basis 
[2, 3].  Chronic AUB was defined as bleeding from the uterine corpus that is abnormal in 
volume, regularity and or timing and has been present for the majority of the last six months.  
Acute AUB was defined as an episode of heavy bleeding that, in the opinion of the clinician, 
is of sufficient quantity to require immediate intervention to prevent further blood loss.  
Intermenstrual bleeding (IMB) is defined as that which occurs between clearly defined cyclic 
and predictable menses and includes both randomly occurring episodes as well as those that 
manifest predictably at the same time in each cycle [2]. 
Heavy menstrual bleeding (HMB) is a sub-category of AUB and has a woman-
centred approach to diagnosis.  Rather than using objective measurements of volume or using 
PBAC (Pictorial Blood Assessment Chart) scores, NICE (National Institute for Care and 
Excellence) define HMB as an excessive menstrual loss that interferes with the physical, 
social, emotional and or material quality of life [4]. This takes precedence over the previously 
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used definitions of menstrual blood loss (MBL) of greater than 80 mL in both research and 
clinical settings [5-7]. 
History of Menstrual Terminology 
 From 430 BC until the early 1800s, the main menstrual symptom appearing in 
medical writings was excessively heavy bleeding [8].  The description of periods in early 
writings also includes phrases such as ‗the flux is immoderate, either when the periods return 
too often, when they continue too long, or when too much blood is discharged at one time‘.  
Irregular and often light bleeding was referred to as ‗the weeping of the womb‘ [9]. 
 The term ‗menorrhagia‘ appears to have been used for the first time in the late 1700s 
in the lectures of Professor William Cullen, Professor of the Practice of Physic at the 
University of Edinburgh.  The term ‗metrorrhagia‘ probably came into use at the same time, 
with Cullen using the spelling ‗maetrorrhagia‘ [10]. 
 The introduction of the confusing modern term ‗dysfunctional uterine bleeding‘ did 
not occur until the 1930s.  Graves used the term ‗dysfunctional uterine bleeding‘ to try and 
explain ‗impairment of endocrine factors‘, which normally controlled menstrual function 
[11]. 
FIGO classification of AUB Aetiology  
Once a diagnosis of AUB has been established the further classification is based on 
the PALM-COEIN Acronym.  The system was developed with contributions from an 
international group of both clinical and nonclinical investigators from 17 countries on six 
continents [3].  This system was created as a detailed assessment of the previously used 
menstrual terminology concluded that there is great confusion in the way these terminologies 
are used and there is an urgent need for international agreement on the consistent use of terms 
and definitions for symptoms, signs, and causes of abnormal uterine bleeding [12, 13]. 
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There are nine main categories, Polyp; Adenomyosis; Leiomyoma; Malignancy and 
Hyperplasia; Coagulopathy; Ovulatory dysfunction; Endometrial; Iatrogenic; and Not yet 
classified.  In general, the components of the PALM group are discrete (structural) entities 
that may be identified visually with imaging techniques and or histopathology, whereas the 
COEIN group is related to entities that are not defined by imaging or histopathology (non-
structural) (Fig 1) [2]. 
The term ―DUB,‖ which was previously used as a diagnosis when there was no 
systemic or locally definable structural cause for AUB should be abandoned [8].  These 
women generally have one or a combination of coagulopathy, a disorder of ovulation, or 
primary endometrial disorder—the last of which is most often a primary or secondary 
disturbance in local endometrial haemostasis [2].  Similarly, the terms menorrhagia and 
metrorrhagia should also be abandoned [3]. 
Demographics 
 There is a significant clinical burden associated with AUB, affecting 14-25% of 
women in the reproductive age group [14, 15].  About 20% of the 1.2 million referrals to 
specialist gynaecologist services concern women with HMB [15].  Current NICE guidance, 
clearly states that HMB should be managed in the context of improving the woman‘s quality 
of life (QoL), rather than treating a target blood loss volume [4].  A recent HMB audit by the 
Royal College of Obstetricians and Gynaecologists (RCOG), assessing patient outcomes and 
experiences in England and Wales, reported that 1-year post referral only 30% of women 
(including those managed with surgery) were ‗satisfied‘ (or better) at the prospect of current 
menstrual symptoms continuing, as currently experienced, for the next 5 years [15]. 
Thus, menstrual problems represent a clinical area of unmet need.  Poor satisfaction 
with standard treatment options often results in women opting for major surgery such as 
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hysterectomy.  Such women would benefit from a tailored approach, both for diagnosis and 
treatment, highlighting the deficiency of biomarkers in this area. 
Advances in genomics have ushered in a new era called ―personalised‖ or ―precision‖ 
medicine, which takes into account individual genetic and other sources of variability in 
disease treatment and prevention.  A strong rationale for the shift towards precision medicine 
was laid by the National Research Council (NRC) [16]. Genomic profiling of endometrium 
may offer a significant step forward, in the healthcare for women with AUB/HMB, both by 
directing patients to most suitable current treatments and also by informing new avenues for 
effective and personalised medical management 
In keeping with the PALM-COEIN classification system, AUB-E possibly represents 
a primary endometrial disorder, while AUB-L and AUB-A, which are still poorly understood, 
potentially, may represent, a secondary endometrial disorder. 
Polyps and AUB (AUB-P) 
Endometrial polyps are epithelial proliferations arising from the endometrial stroma and 
glands.  The majority are asymptomatic The reported prevalence of endometrial polyps varies 
widely and ranges from 7.8% to 34.9%, depending on the definition of a polyp, the diagnostic 
method used, and the population studied [17-20].  There are no identified biomarkers for 
polyps in clinical use, and their diagnosis relies on imaging; ultrasonography (USS), 
sonohysterography and hysteroscopy [4]. 
Adenomyosis and AUB (AUB-A) 
Adenomyosis is defined as the presence of ectopic endometrial glands and stroma in 
the myometrium, although it remains a poorly understood entity.  The prevalence of 
adenomyosis is difficult to ascertain because of a wide variation in diagnostic criteria both 
with imaging modalities and with histology.  It has been estimated that histological 
confirmation of adenomyosis ranges from 5-70% of patients who undergo hysterectomy [21].  
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Adenomyosis is thought to cause HMB, dysmenorrhea and infertility [22] although not all 
studies agree that HMB is a causal association [23]. 
Risk factors for adenomyosis include increasing parity, termination of pregnancy, 
uterine curettage and caesarean birth, all of which may disrupt the endo-myometrial junction 
and thereby allow infolding of the endometrium with direct myometrial invasion [24, 25].  
There also appears to be an association between oestrogen exposure and development of 
adenomyosis.  Increasing age with increased duration of oestrogen exposure, tamoxifen use 
positively correlate with adenomyosis risk [26], interestingly, cigarette smoking may be 
protective [27].  Increasing age with cellular damage and repair may be contributory.  Other 
gynaecological conditions that may be associated with adenomyosis include uterine fibroids 
and endometriosis, although there is a debate if the latter is a separate entity at all [28].  At a 
cellular level, matrix metalloproteinases (MMP)s may initiate damage to the endo-
myometrial junction via the basement membrane [29], and Cyclo-oxygenase (COX) 
enzymes, Vascular Endothelial Growth Factor (VEGF) and stem cell progenitors may 
contribute to the development of adenomyosis [30, 31].  
In a study by Li et al, aberrations in angiogenesis were proposed as mechanisms to 
explain histological changes in adenomyosis.  A positive correlation was observed between 
VEGF expression and MMP-2 and MMP-9 expression. A positive correlation was also found 
between mean vessel diameter (MVD) and MMP-2 or MMP-9 expression.  It seems, 
therefore that the elevation of MMP-2 or -9 expression may represent an important factor in 
the development of the disease, contributing to the invasion of endometrial tissues into the 
myometrium and angiogenesis in adenomyotic implants [32].  
Recent evidence also points to epithelial-mesenchymal transition (EMT) in the 
pathogenesis.  Epithelial to mesenchymal transition (EMT) is a process characterised by a 
loss of polarity of epithelial cells and transition to a mesenchymal phenotype, which at a 
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molecular level involves down-regulation of epithelial markers (e.g., E-cadherin) and 
overexpression of mesenchymal markers (e.g., fibronectin and vimentin), and activation of a 
number of transcription factors, including Snail, Slug, Twist, Zeb1, and SIP1 [33].  
Reduced apoptosis and increased proliferation of the eutopic endometrium could play 
a role in the pathophysiology of adenomyosis [34].  This was further quantified using a Ki-67 
(a nuclear and nucleolar protein that is strictly associated with cell proliferation) labelling 
index by Yang and colleagues [35].  The study involved analysing eutopic endometrium in 
premenopausal women with and without adenomyosis who underwent a hysterectomy.  The 
endometrium was separated into endometrial stromal cells (ESCs).  Markers for proliferation 
were investigated using non-radioactive assay kits, and immunohistochemistry (IHC) and 
those for apoptosis was analysed using Fluorescence-activated cell sorter.  Sotnikova et al 
have suggested impaired cytokine production in the development of adenomyosis [36].  
Studies also propose an increased synthesis of local oestrogen and possibly, 
progesterone resistance in women with adenomyosis.  Increased aromatase and estrone 
sulfatase activity in glandular cells of eutopic and ectopic endometrial tissues in women with 
adenomyosis can contribute to increased local uterine/endometrial oestrogen production, and 
reduced Progesterone receptor B isoform (PR-B receptors) may contribute to local 
progesterone resistance [37, 38]. 
The concept of repeated tissue injury and repair in women with adenomyosis is 
supported in a study by Liu and colleagues.  They propose that platelet-induced activation of 
the TGF-β/Smad signalling pathway may be a driving force in epithelial-mesenchymal 
transition (EMT). fibroblast-to-myofibroblast transdifferentiation (FMT), and smooth muscle 
metaplasia (SMM) in the development of adenomyosis leading to fibrosis.  Platelets may also 
be involved in uterine hyperactivity and myometrial hyperinnervation, potentially 
contributing to adenomyosis symptoms [39]. 
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Diagnosis of adenomyosis is based on histology (at hysterectomy) and imaging.  The 
common imaging modalities used for non-histological diagnosis of adenomyosis include 
transvaginal ultrasound (TVUS) and Magnetic Resonance Imaging (MRI), although a clear 
consensus on imaging criteria remains lacking.  A recent systematic review confirms that 
TVUS 2D is effective and should be considered as the first line ultrasound imaging method 
for the diagnosis of adenomyosis.  Enhancing tools such as TVUS 3D improved upon 
sensitivity when used with poor definition of the junctional zone, while no improvement was 
noted in the overall sensitivity compared to TVUS 2D [40].  Newer imaging techniques such 
as elastography in addition to conventional ultrasound may hold potential in the future to 
assist with diagnosis of uterine focal lesions and may be useful in preoperative planning [41].  
A recent study has also proposed that TV Elastography can improve the diagnostic accuracy 
for adenomyosis, especially in differentiating it from uterine fibroids.  The study also 
suggests a role for elastography in the assessment of the developmental stage of adenomyotic 
lesions and a guide for the best treatment modality for the patient [42]. 
A meta-analysis comparing TV US and MRI in the adenomyosis concluded that both 
techniques showed high levels of accuracy, although a correct diagnosis was obtained more 
often with MRI [43].  The Morphological Uterus Sonographic Assessment (MUSA) group 
has proposed uniform criteria for the diagnosis of both uterine fibroids and adenomyosis to 
facilitate consistent reporting of in both daily clinical practice and for research purposes [44, 
45]. 
Several biomarkers have been explored in research settings for diagnosing 
adenomyosis, but none have been adapted for clinical use. Caveolin (CAV) proteins are the 
fundamental components of caveolae that form different structural and functional 
microdomains in a wide variety of cell types.  A study evaluated the expression of CAV 1 in 
the ESCs in the human uterus affected by adenomyosis and concluded that loss of stromal 
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CAV1 expression may play a critical role in the pathogenesis of adenomyosis.  Loss of 
stromal CAV1 expression enhanced metastasis of ESCs and enabled increased growth, 
migration and invasion of endometrial epithelial cells (EECs) that might involve the release 
of RANTES in the stroma of the ectopic lesion. RANTES (also termed CCL5), a chemokine 
for monocytes and activated T cells significantly correlates with the severity of stages and 
dysmenorrhea in women with deep infiltrating endometriosis (DIE).  The expression level of 
RANTES in the ectopic ESCs of adenomyosis patients was significantly higher than that of 
the eutopic counterpart. Silencing of stromal CAV1 in ESCs could trigger nitric oxide (NO) 
and prostaglandin E2 (PGE2) production in ESCs, potentially contributing to the symptom of 
dysmenorrhea [46]. 
Moesin a protein encoded in human by the MSN gene has been proposed as a 
biomarker for adenomyosis.  Using proteomic analysis, a higher expression of moesin was 
noted in adenomyosis versus normal endometrium.  This was initially identified using IHC 
with a higher expression in ESC than in EEC and confirmed using RT-PCR and Western 
Blot.  An association between moesin as a marker for EMT has been already proposed and 
may contribute to our understanding of the pathophysiology of adenomyosis.  Adenomyosis 
development mimics the process of tumour metastasis, which is characterised by progressive 
trans-myometrial invasion of endometrial cells and neovascularisation in ectopic lesions.  To 
explain the invasiveness seen in adenomyosis, the authors propose a further review of the 
phosphorylation of moesin in women with adenomyosis, as in certain tumours such as 
invasive gastric adenocarcinoma, the extent of invasiveness correlates with moesin 
expression [47]. 
A common method employed for biomarker discovery is Proteomics, which is, in 
essence, a large-scale study of proteins.  Proteomic-based approaches for biomarker 
investigation can be employed in different aspects of medicine, such as elucidation of 
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pathways affected in disease, identification of individuals who are at a high risk of 
developing disease for prognosis and prediction of response, identification of individuals who 
are most likely to respond to specific therapeutic interventions, and prediction of which 
patients will develop specific side effects. Proteomics analysis has been used to compare the 
differential protein expression profile between matched ectopic and eutopic endometrium of 
adenomyosis.  The study showed that a group of oestrogen-responsive proteins were 
significantly altered and amongst them, Annexin 2 (ANXA2) was identified as a key player 
in adenomyosis development by inducing both metastasis and proangiogenesis of 
adenomyotic endometrial cells.  The invasive and metastatic potential involved in 
adenomyosis was achieved by ANXA2-induced β-catenin/T Cell factor associated EMT-like 
switch in endometrial cells and the proangiogenic capacity in local lesion was enhanced via 
ANXA2/HIF-1α/VEGF-A pathway activation [48]. 
Proteomic analysis using matrix-assisted laser desorption ionisation time-of-flight 
mass spectrometry (MALDI-TOF-MS) has been studied in women with adenomyosis and 
endometriosis.  The study compared protein peaks using the MALDI-TOF-MS system in the 
serum of women with endometriosis or adenomyosis to controls and identified a possible 
biomarker for the conditions, but was unable to differentiate between endometriosis and 
adenomyosis [49]. 
The nuclear factor nuclear factor kappa light chain enhancer of activated B cells (NF-
κB) pathway has long been considered a proinflammatory signalling pathway, largely based 
on the role of NF-κB in the expression of proinflammatory genes including cytokines, 
chemokines, and adhesion molecules. It also plays an important role in apoptosis and cellular 
growth [50].  NF-κB activity is regulated by a family of proteins known as IκBs.  There are 
two pathways of (NF-kB) activation that are known currently.  The canonical pathway is 
triggered by microbial products and proinflammatory cytokines such as TNFα and IL-1, 
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while the alternative pathway is triggered by TNF-family cytokines but not TNFα [51, 52].  
Immunoreactive proteins have been studied as potential biomarkers, including p65, p50 and 
p52.  Nuclear p65 immunoreactivity was positively associated with heavier menses and 
decreased PR-B, and increased nuclear p65 immunoreactivity in the ectopic endometrium 
was associated with the severity of dysmenorrhea in women with adenomyosis [34, 38]. 
Huang et al proposed that an imbalance between apoptosis and proliferation may 
contribute to the pathogenesis and progression of adenomyosis.  The presence of ectopic 
endometrium in adenomyosis is likened to a tumour like invasiveness, although poorly 
understood [53].  Tyrosine kinase receptor B (TrkB), is a neurotrophic receptor and 
contributes to tumour cells‘ resistance to apoptosis, and the acquisition of invasive and 
metastatic abilities [54].  Moreover, overexpression of TrkB in several types of human 
malignancy supports this hypothesis.  The study concluded that TrkB protein and TrkB 
mRNA in adenomyotic endometrium was elevated and positively correlated with the degree 
of dysmenorrhea.  This may contribute to our understanding of the pathogenesis of 
adenomyosis and may represent a potential biomarker for disease progression in the future 
[53]. 
Tissue factor (TF) is a cell membrane-bound glycoprotein and a member of the 
cytokine receptor family [55].  TF is mainly expressed in ESC and is regulated by 
progesterone.TF is involved in the pathogenesis of endometriosis, possibly in angiogenic and 
inflammatory signalling and has been evaluated as a biomarker in women with endometriosis 
[56].  TF elevation in women with endometriosis is thought to explain symptoms of 
dysmenorrhea and HMB, and given the similarities between endometriosis and adenomyosis, 
the authors proposed to identify elevated TF expression in women with adenomyosis [57].  
The study showed increased TF immunoreactivity in the adenomyotic endometrium (eutopic 
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and ectopic) versus controls (no adenomyosis) and had a strong association with HMB and 
dysmenorrhea [57]. 
SLIT is a secretory glycoprotein which acts via its receptor ROBO, a transmembrane 
protein. SLIT-ROBO system is reported to function as a chemoattractant to recruit vascular 
endothelial cells to sites for vasculogenesis [58].  Increased SLIT expression correlates with 
increased MVD and is a marker for tumour angiogenesis [59].  SLIT immunoreactivity is 
increased in endometriosis.  Its elevation may be a constitutive biomarker for recurrence of 
endometriosis, and given the similarities between adenomyosis and endometriosis, SLIT has 
been explored as a potential biomarker in women with adenomyosis [60].  In comparison to 
the normal endometrium, Nie and colleagues demonstrated that SLIT expression was higher 
in the ectopic endometrium of women with adenomyosis, while ROBO1 immunoreactivity 
and MVD were higher in both eutopic and ectopic endometria of women with adenomyosis 
and that these biomarkers positively correlated with the severity of dysmenorrhea [61].  Table 
1 summarises the researched biomarkers and potential pathogenetic mechanisms of 
adenomyosis. 
Leiomyomas and AUB (AUB-L) 
Uterine fibroids (myomas, leiomyomas) are the most common benign tumours in 
women of reproductive age present in almost 80% of all women by the age of 50 [62].  
Fibroids tend to be twice or even three times more common in black women as compared to 
other racial or ethnic groups [63].  The association between AUB and fibroids is complex and 
poorly understood, as women with fibroids may be asymptomatic; however, a strong 
association exists between submucous myomas and AUB, demonstrated as early as 1956 
[64]. 
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The proposed mechanisms of how fibroids may cause AUB include an increase in the 
endometrial surface, an increase in uterine vascularisation, changes in patterns of myometrial 
contractility, ulceration of the surface of a myoma, myoma degeneration and uterine venous 
ectasia by compression effect from the myoma(s) [65].  These proposed mechanisms often 
relate to fibroid size, but cannot explain completely, the relationship between AUB and 
fibroids.  There is a correlation between AUB and the degree of distortion and penetration of 
the uterine cavity associated with the fibroid(s).  Submucous myomas (FIGO 0, 1, 2 and 3) 
are thought to be most symptomatic [66].  Distortion of the uterine cavity by fibroids is also 
proposed to explain other symptoms such as infertility [67]. 
In recent years, our understanding of fibroids at a molecular level and cellular has 
significantly improved.  Although several potential biomarkers have been identified 
(discussed below), none are in clinical use.  It is well established that fibroids are monoclonal 
tumors arising from the smooth muscle cells of the myometrium.  Fibroids contain three 
different cell populations: fully differentiated smooth muscle cells, intermediate cells and 
fibroid stem cells, which in turn are crucial to fibroid growth.  A genetic hit in the myometrial 
stem cell can produce fibroid stem cells.  These genetic hits include mutations in the 
Mediator Complex (MED) 12 gene and chromosomal rearrangements on the High Mobility 
Group A (HMG2A) gene on the long arm of chromosome 12 [68-71].  
Endocrine-disrupting chemicals (EDCs), are substances in our environment, food, and 
consumer products that interfere with hormone biosynthesis, metabolism, or action resulting 
in a deviation from normal homeostatic control or reproduction and there is evidence to 
suggest that exposure to EDCs, especially in critical phases of uterine development such as 
in-utero and early childhood may result in genetic mutations influencing fibroid growth [72, 
73]. 
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Fibroids are steroid hormone-dependent tumours however, unlike differentiated 
fibroid cells, fibroid stem cells have a very low expression of oestrogen and progesterone 
receptors, indicating that these hormones exert their tropic effects on fibroid stem cells via a 
paracrine mechanism.  Fibroids also secrete increased Transforming Growth Factor – Beta 3 
(TGF-3) in response to steroids (see below). TGF-3 is a cytokine, which is involved in cell 
differentiation, embryogenesis and development and is believed to regulate molecules 
involved in cellular adhesion and extracellular matrix (ECM) formation.  TGF- has a direct 
effect on fibroid ECM production, stimulating collagen expression as well as plasminogen 
activator inhibitor-1 expression [74].  The role of TGF- in fibrotic processes such as liver 
cirrhosis, pulmonary fibrosis is well established, and further research may improve our 
understating of fibrotic pathways associated with fibroids [75]. 
The role of the WNT/-catenin pathway is also of importance in fibroid growth.  
Mutations in MED 12 genes are believed to lead to alterations in the WNT/B-catenin 
pathway expression and signalling. This results in degradation of cytoplasmic -catenin and 
increased nuclear -catenin, which is associated with increased fibroid burden in murine 
models [76, 77].  In human fibroid cells, silencing the MED 12 gene results in decreased 
WNT/-catenin pathway signalling, thereby slowing fibroid growth [70].  The WNT/-
catenin pathway also results in increased expression of TGF-3. A recent study by Sinclair et 
al suggested that leiomyoma-secreted TGF-3 induces BMP-2 resistance in the endometrium 
by downregulation of BMPR-2, likely causing defective endometrial decidualisation. TGF-3 
also reduces expression of PAI-1, ATIII, and thrombomodulin in the endometrium, likely 
contributing to AUB/HMB. In the past, TGF-3 has been shown to be involved in 
extracellular matrix remodeling and proliferation which could modulate fibroid growth [78]. 
AUB/HMB associated with fibroids may be explained by a complex interplay 
between coagulation, neo-angiogenesis and vasoconstriction.  As described above fibroids 
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secrete TGF-3, which in turn may alter normal haemostatic and fibrinolytic pathways 
through PAI-1, ATIII, and thrombomodulin in endometrium [78].  Evidence also suggests an 
increased expression of fibroblast growth factor and fibroblast growth factor receptor, in the 
endometrium of women with fibroids [79].  Other angiogenic factors such as heparin binding 
epidermal growth factor, platelet derived growth factor, vascular endothelial growth factor, 
parathyroid hormone-related protein and prolactin are also altered in women with fibroids 
[80].  This could explain altered neo-angiogenesis and HMB with fibroids. Endothelin-1 
(ET), Prostaglandin F2 Alpha (PGF2) are potent vasoconstrictors that regulate menstruation 
[81].  Vasoconstrictors that regulate myometrial contractility (Endothelin-1, Prostaglandin F2 
Alpha) and spiral arteriole vasoconstriction (Endothelin-1), are altered in women with 
fibroids [82, 83].  PGF2 production is increased in women with uterine fibroids [82].  
Endothelin-1 acts via the ETA-R and ETB-R receptors and higher levels of Endothelin-1 have 
identified in the endometrium as compared to the fibroid tissue and myometrium.  In 
addition, higher levels of ETA-R are identified in the myometrium compared to fibroid tissue 
and vice versa for ETB-R.  These alterations suggest disordered ET function in women with 
uterine fibroids [83].  The consequence of perturbed expression of these vasoconstrictors 
results in alerted myometrial contractility and dilatation of endometrial stromal venous spaces 
and may explain HMB associated with fibroids. 
Changes in circulating levels of cytokines such as Interleukins (IL) -10, 13, 17 have 
been identified in women with fibroids [84]. In general, an infection is accompanied by an 
inflammatory process;  however, an inflammatory response evidenced by altered cytokine 
levels in the endometrium (out with infection), as a mechanism for HMB associated with 
fibroids, remains to be established. 
A clinical and functional genomics analysis in women with fibroids was undertaken 
and concluded that that intramural leiomyomas not affecting the endometrial cavity alters the 
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expression pattern of some endometrial genes, but the genes involved in implantation are not 
affected.  The study identified that the expression of 69 genes strongly correlated with the 
size of the myoma, and 26 genes did so positively, whereas 43 did so negatively.  Among the 
genes that were up-regulated with the size of the intramural fibroid, there was an association 
with larger blood vessel size, a feature that correlates well with the angiogenesis involved in 
fibroid vascular supply and growth.  Similarly, immune response and response to wounding 
were underrepresented when a fibroid was present.  An impairment of maturation and 
differentiation of lymphocytes in women with large leiomyomas suggested a decrease in the 
local immune response [85]. 
Despite all the advances discussed above, a biomarker for identifying causal factors 
underlying AUB in women with fibroids remains elusive currently, and reliance for 
identifying the presence of uterine fibroids is placed on imaging modalities (USS, MRI, 
sonohysterography) and hysteroscopy. Table 2 summarises the researched biomarkers and 
potential pathogenetic mechanisms of leiomyomas. 
Malignancy and AUB (AUB-M) 
It is beyond the scope of this article to discuss malignancy related biomarkers as it is 
primarily focused on benign pathology. 
Coagulopathy and AUB (AUB-C) 
Coagulopathies are reported to affect 13% of the women presenting with HMB [86].  
The systemic disorders of haemostasis may be identified in 90% of women using a structured 
history. See Table 3 [87]. 
There are clearly defined biomarkers for this cause of AUB, so long as health 
professionals are meticulous at screening women at risk and offering onward referral to 
appropriate specialists.  These biomarkers include a full blood count (FBC), measurement if 
individual coagulation factor quantity and/or activity, D-Dimer, Fibrinogen, International 
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Normalised Ratio (INR), Partial Thromboplastin Time (PTT), Prothrombin Time (PT), 
Thrombin Time (TT), Platelet function test, Ristocetin Cofactor (VWF: RCo), von 
Willebrand Factor (VWF) Antigen (VWF: Ag) and several more. It is beyond the scope of 
this article to discuss individual biomarkers for AUB-C. 
In the original FIGO PALM-COEIN system, women with AUB associated with the 
use of anticoagulants were categorised with coagulopathies (AUB-C). In the updated 
classification (2018), they are considered iatrogenic and classified as AUB-I. This includes 
the modern, non-vitamin-K antagonists such as rivaroxaban that appears to have a greater 
impact on the volume of menstrual bleeding than the traditional, vitamin K antagonists such 
as warfarin [13, 88]. 
Ovulatory disorders and AUB (AUB-O) 
 Anovulation is observed at extremes of age, in association with endocrine disorders 
such as hypothyroidism, polycystic ovarian syndrome (PCOS), hyperprolactinemia and with 
factors such as mental stress, extremes of weight, excess exercise and even drugs that 
interfere with the hypothalamic-pituitary-ovarian (HPO) axis such as dopamine agonists. 
Anovulatory cycles tend to present as an alteration in cycle length (often >38 days) and 
AUB/HMB due to the effect of unopposed oestrogen on the endometrium. 
 Although a well-structured history and examination, may identify many cases, 
specific tests may be ordered to rule out endocrinopathies.  Thus, there are clinically relevant 
biomarkers for this cause of AUB, such as serum thyroid stimulating hormone (TSH) and 
thyroxine levels, prolactin levels, gonadotropin levels (FSH/LH), sex hormone binding 
globulin (SHBG), free androgen index (FAI) and so on. It is beyond the scope of this article 
to discuss individual biomarkers for endocrinopathies contributing to AUB-O. 
 Bao et al, have presented data to identify serum amyloid protein A (SAA) as a 
potential biomarker to differentiate between ovulatory and anovulatory AUB.  Using surface 
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enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS), 
they identified 3 protein peaks corresponding to SAA, vascular endothelial growth factor 
(VEGF) and anti-vitamin K epoxide reductase (VKOR). Given that SAA is highly expressed 
in individuals with non-immune inflammation, the authors hypothesised a similar response in 
women with AUB, that SAA was highly expressed in the menses (sera and supernates) of 
anovulatory and ovulatory women with AUB versus controls.  The role of VEGF is well 
established in menstruation and endometrial repair [89].  In this study, VEGF was highly 
expressed in ovulatory women with AUB but poorly expressed in anovulatory patients 
suggesting a possible aberration in angiogenesis in anovulatory AUB.  Vitamin K is essential 
in the clotting cascade and requires VKOR for this process.  The authors noted a poor 
expression of VKOR in the menses of women with ovulatory AUB possibly suggesting a 
defect in clotting [90]. 
Endometrial Disorders and AUB (AUB-E) 
 AUB that occurs in the absence of an identifiable histological or structural cause 
(AUB-L, AUB-A, AUB-P), in the context of regular menstrual cycles (ovulatory) and with 
coagulopathy ruled out, in the absence of iatrogenic causes (AUB-I) usually represents a 
primary endometrial disorder (AUB-E).  AUB-E is thought to be caused by a local 
disturbance(s) in endometrial function– deficiencies or excesses of proteins or other entities 
that have an adverse impact on hemostasis, normal angiogenesis, vascular integrity, or 
endometrial repair. AUB-E is a diagnosis of exclusion; a well-structured history and 
examination often help, but there is no commercially available testing.  Hence a clear role for 
developing biomarkers exists for this cause of AUB.  
 The endometrium is a complex multicellular tissue that lines the inside of the 
endometrial cavity and involves interactions of immune, endocrine and vascular systems.  It 
is morphologically divided into functional and basal layers.  The functional layer occupies 
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the upper two thirds of the endometrium.  During endometrial repair and proliferation, 
mitosis occurs in the functional layer of the endometrium. a highly active layer consisting of 
glands supported by stroma.  Studies now demonstrate that the basal layer may not serve as a 
source of stem cells for endometrial regeneration after normal menstruation. Instead, changes 
in the microenvironment may reprogram the few functional cells remaining after 
menstruation to regenerate a new functional layer [91]. 
 It is well established that progesterone withdrawal secondary to the demise of the 
corpus luteum in the absence of pregnancy, is the signalling event for the onset of 
menstruation.  A key role is played by decidualised ESCs, as they remain responsive to 
progesterone through the secretory phase.  They retain progesterone receptor (PR) 
expression, thereby allowing the endometrium to respond to progesterone withdrawal.  
Progesterone withdrawal is proposed to have two major effects; a) increased levels of 
cytokines and prostaglandins into the endometrium and consequently b) influx of leucocytes, 
activation of matrix metalloproteinases (MMPs) and destruction of the extracellular matrix 
[92].  The action of MMPs is thought to be independent to progesterone withdrawal after an 
initial inflammatory response.  
Neutrophils type leucocytes predominantly increase in the endometrium and contain 
high levels of MMPs and can activate local MMPs, initiating endometrial breakdown. 
Increased B cell lymphoma 2 (BCL 2 – an apoptosis regulator) levels secondary to 
progesterone withdrawal, limiting neutrophil activity in the endometrium and prevent a 
damaging chronic inflammatory response [93].  Macrophages also increase perimenstrually 
and produce cytokines and proteases and are involved in tissue remodelling and debris 
removal [94, 95]. 
Inflammatory responses in the endometrium are mediated via the NF-B pathway, 
secondary to steroid hormone withdrawal. NF-kB increases the transcription of a wide variety 
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of genes, including cytokines (IL-1, IL-6), chemokines (CXCL8/IL-8, chemokine ligand 
2/CCL-2) and adhesion molecules [96].  Increased IL-8 mRNA expression in premenstrual 
endometrium and localisation to perivascular cells by the withdrawal of progesterone has 
been shown by Milne et al [97].  A role for cyclo-oxygenase (COX)-2 following progesterone 
withdrawal has also been demonstrated [98].  Inhibition of the COX enzymes or NF-kB at the 
time of progesterone withdrawal significantly decreased the amount of bleeding and 
endometrial breakdown and leucocyte influx in a murine model [99]. 
Menstruation has been proposed to occur also as a result of a physiological process of 
ischemia and reperfusion.  Ischaemia has not been detected in the human endometrium 
during menstruation to date, however evidence supports the occurrence of hypoxia in the 
endometrium.  Markers for hypoxia [CAIX and hypoxia inducible factor-1 (HIF-1)] have 
been detected in the human endometrium during menstruation [100].  The current evidence 
supports the role of hypoxia and HIF-1 in the process of endometrial repair during 
menstruation [101]. 
Vasoconstriction of the uterine spiral arterioles mediated by PGF2  and Endothelin -1 
is considered to play a role in determining blood loss during menstruation. PGE2 is known to 
have a vasodilatory effect [102].  Evidence supports the theory of HMB secondary to a 
reduced endometrial expression of ET-1 and an altered PGF2 / PGE2 ratio.  The reduced 
maturity of the uterine spiral arteriole vessel wall, increased gaps in the endothelial cell lining 
and reduced vascular smooth muscle proliferation, may all contribute to HMB [103-106]. 
Cessation of menstruation relies on an intact endometrial coagulation system. 
Endometrial endothelial injury initiates immediate activation and aggregation of platelets to 
form a plug.  The subsequent stage of haemostasis involves the formation of fibrin via the 
coagulation cascade.  Tissue plasminogen activator (t-PA) and urokinase plasminogen 
activator (u-PA) drive the production of plasmin and plasminogen activator inhibitor (PAI) 
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inhibits fibrinolytic activity [107].  There is evidence that an overactive fibrinolytic system in 
the endometrium interferes with haemostasis and contributes to HMB [108]. 
Angiogenesis and spiral arteriole maturation is essential components of repair during 
menstruation, a process that‘s usually completed by cycle day 5.  Vascular endothelial growth 
factor (VEGF), a key mediator of vascular function, is increased in women at menses, and is 
regulated by hypoxia [109].  This process is independent of steroid hormones.  Recently 
interest has increased in the role of immune cell influx at the time of menstruation the role 
they may play in the regulation of endometrial bleeding.  The uterine natural killer (uNK) 
may cells play an important role in spiral arteriole maturation, which in turns will impact 
upon vasocontraction and potentially reduced menstrual blood loss [110].  Dysregulation of 
uNK cells in HMB has also been demonstrated, which may have an impact on endometrial 
vascular development and or endometrial preparation for menstruation. [111]. 
Newer research has focussed on the role of hypoxia and the HIF-1 in endometrial 
repair using a murine model of simulated menstruation.  Validation of the mouse model of 
menstruation has already been performed [95].  The study by Maybin et al demonstrated 
reduced endometrial HIF-1 in women with AUB/HMB. The study suggests that HIF-1α 
regulates response within cells to low oxygen levels (hypoxia), increasing the production of a 
number of repair factors and therefore playing an important role in repair of the denuded 
endometrial surface [101]. 
Despite the vast improvements in the understanding of the cellular and molecular 
basis of menstrual physiology, clinically usable biomarkers remain lacking in women with 
AUB-E. 
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Iatrogenic AUB (AUB-I) 
AUB may be associated with the use of exogenous steroids, usually as continuous 
oestrogen and or progesterone therapy results in unscheduled bleeding (BTB) [112].  Drugs 
that interfere with ovarian steroid release may have a similar effect (GnRH agonists and 
antagonists) and aromatase inhibitors.  The use of Intrauterine Contraceptive Devices 
(IUCDs) may contribute to chronic endometritis and AUB [113].  A structured history and 
examination and exclusion of other causes help to secure the diagnosis.  Often cessation of 
the drug or removal of the device (implant, intrauterine device) helps resolve the problem.  
The role of biomarkers in this category is limited. 
Not otherwise classified (AUB-N)  
Entities such as chronic endometritis (not secondary to IUD use), arteriovenous 
malformations (AVMs) [114], endometrial pseudoaneurysms and myometrial hypertrophy 
have been associated with or contribute to AUB/HMB.  Caesarean sections scar defects such 
as ―isthmoceles‖ may also contribute to AUB [115, 116].  In addition, there may be other 
disorders that would be defined only by biochemical or molecular biology assays that should 
be placed in this category.  Considering these entities are extremely rare, the search for a 
viable endometrial biomarker is only of academic value. 
Most women with AVMs, endometrial pseudoaneurysms and myometrial hypertrophy 
will be diagnosed using imaging techniques.  Chronic endometritis (CE) is poorly understood 
but plays an important role in AUB and poor reproductive outcomes and is currently 
diagnosed by histology.  A study by Tortorella et al, proposed the use of biomarkers in the 
menstrual effluent for diagnosing chronic endometritis.  They identified that proinflammatory 
cytokines are increased in menstrual effluents of women with CE with IL-6 and TNF-alpha 
having a high screening capacity for the condition [117].  The role of Chlamydia Trachomatis 
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and AUB has also been described and its prevalence is thought to be underestimated as a 
cause of AUB [118]. 
 
Future Directions 
Although to date, there is a limited success in the clinical use of biomarkers for 
women with AUB, this remains an area of unmet need.  In a medical context, the word 
―phenotype‖ is used to refer to some deviation from normal morphology, physiology, or 
behaviour.  Deep phenotyping can be defined as the precise and comprehensive analysis of 
phenotypic abnormalities in which the individual components of the phenotype are observed 
and described.  The emerging field of precision medicine aims to provide the best available 
care for each patient based on stratification into disease subclasses with a common biological 
basis of disease [119].  There is a clear need for developing a system of deep phenotyping for 
women with AUB, such that individualised and personalised care can be offered, to ensure 
best results with treatment strategies. 
A role for the endometrial microbiome has been proposed, and a study by Pelzer et al 
using microbial community profiling revealed differences in the endometrial microbial 
community profiles for: (1) the endocervix compared to the endometrium, and (2), women 
with HMB versus dysmenorrhea [120].  This allows for further exploration in this field, to try 
and understand the pathogenesis and develop management strategies for women with AUB. 
The role of exosomes using proteomic analysis in predicting adverse pregnancy 
outcomes and suggesting pathophysiologic mechanisms has been explored in the context of 
preterm birth [121].  Exosomes act as proxies for cells and therefore serve as better 
biomarkers than secreted biochemicals from cells. Exosomes may hold a role in the future as 
tools for ―non-invasive‖ tissue sampling in women with AUB.  Exosomes derived from 
menstrual blood have already been used for other applications [122]. This remains an 
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unexplored field with the potential to discover new biomarkers. Uterine fluid obtained by 
lavage or as aspirates, menstrual loss supernatants and sera may all have a future role to play 
[90, 123].  
Current pathology practice utilises chromogenic immunohistochemistry (IHC) and 
improving the technology available, may allow us to identify clinically usable biomarkers.  
Multiplexed IHC (mIHC) approaches are now available, offering greater insights into disease 
heterogeneity and the characterisation of systems biology mechanisms driving disease, as 
well as helping to conserve limited tissues. mIHC offers greater insight into molecular 
cascades, preserves tissue context and allows for improved accuracy through the application 
of image analysis, with the use of landmark markers specifically to indicate tissue 
architecture [124].  Application of such technology has already been used in the field of 
cancer. Kim et al have demonstrated quantitative proteomic profiling of breast cancers using 
mIHC, so that individualised cancer therapy can be offered [125]. 
In keeping with advances in technology, elastography (MRI and USS), is being 
increasingly used in the assessment of women with fibroids and adenomyosis serving as non-
invasive imaging biomarkers.  More importantly there are being used to tailor therapy and 
predict treatment response for allowing individualised care [126].  A recent study showed 
that fractional change in stiffness value of uterine fibroids measured by magnetic resonance 
elastography (MRE) would be related with the treatment outcomes after magnetic resonance 
guided focused ultrasound (MRgFUS) [127]. 
Identifying differential gene expression in women with AUB/HMB i.e. a gene 
signature may advance our understanding of the mechanisms responsible for HMB and 
allowed tailored treatment strategies.  Steps in this direction have already been made [128]. 
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CONCLUSION 
AUB is a common and frequently debilitating condition for women worldwide. It has 
clinical implications and a high cost for the healthcare system. Uterine fibroid tumours were 
estimated to cost the United States $5.9-34.4 billion annually [129].  HMB is a subjective 
diagnosis affecting women across the globe.  The PALM-COEIN acronym maybe be used as 
a foundation of care; it improves the understanding of the causes of AUB, and in doing so 
facilitates effective history taking, examination, investigations and management [2, 13].  A 
range of medical and surgical management options are available, the choice of which is 
guided by the underlying cause of AUB alongside the woman‘s co-morbidities, fertility 
wishes and personal preference in women with AUB-L and AUB-A. 
The classification system reveals the lack of effective biomarkers, especially for 
AUB-E.  Tailoring treatments to target increased inflammation, vascular dysfunction and 
delayed endometrial repair in women with AUB-E should increase compliance, reduce the 
need for surgery, preserve fertility (if desired), improve outcomes and patient satisfaction. 
Although several potential biomarkers have been discussed in this review, the 
limitations are that many biomarker studies have only a small number of samples, and studies 
have not been repeated or validated.  
Key factors in the development of technologies for personalised medicine are 
standardisation, integration and harmonisation.  For example, the tools and processes for data 
collection and analysis must be standardised across research sites.  Research activity at 
different sites must be integrated to maximise synergies, and scientific research must be 
integrated with healthcare to ensure effective translation.  There must also be harmonisation 
between scientific practices in different research sites, between science and healthcare and 
between science, healthcare and wider society, including the ethical and regulatory 
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frameworks, the prevailing political and cultural ethos and the expectations of 
patients/citizens [130]. 
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Figure 1. FIGO classification of causes of AUB; ‘PALM-COEIN’ 
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Table 1  Researched Biomarkers & Potential Pathogenesis in Adenomyosis 
 
 Increased MMP expression [32] 
 Epithelial Mesenchymal Transition (EMT) [33] 
 Increased Proliferation (KI-67) and Reduced apoptosis in the eutopic endometrium [35] 
 Increased local oestrogen production -Increased aromatase and oestrone sulfatase activity [35] 
 Increased local progesterone resistance mediated by Progesterone receptor B isoform (PR-B 
receptors) [38] 
 Repeated tissue injury and repair - Platelet-induced activation of the TGF-β/Smad signalling 
pathway [39] 
 Reduced expression Caveolin (CAV) proteins [44] 
 Increased Moesin expression [47] 
 Increased Annexin 2 (ANXA2) expression [48] 
 Activation of NF-κB [51, 52] 
 Increased expression of TrkB [51,52] 
 Increased SLIT/ROBO expression [60, 61] 
 Imaging - Elastography [41, 42] 
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Table 2  Researched Biomarkers & Potential Pathogenesis – Fibroids 
 
 Chromosomal rearrangements on the High Mobility Group A (HMG2A) gene [71] 
 Mutations in the Mediator Complex (MED) 12 gene [68-70] 
 Exposure to Endocrine-disrupting chemicals (EDCs) [72, 73] 
 Increased production of Transforming Growth Factor – Beta 3 (TGF-3) with increased BMP-2 
resistance [74] 
 WNT/-catenin pathway [70, 76-78] 
 Altered cytokines such as Interleukins (IL) -10,13,17 [84] 
 Imaging – Elastography [41] 
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Table 3  Detection of Coagulopathies (Adapted from Kouides et al [87]) 
 
Structured history—positive screen if 
a. Excessive menstrual bleeding since menarche, or 
b. History of one of the following—postpartum haemorrhage, surgery-related bleeding, or bleeding 
associated with dental work, or  
c. History of two or more of the following— bruising greater than 5 cm once or twice/ month, epistaxis 
once or twice/month, frequent gum bleeding, family history of bleeding symptoms.  
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